Morgan Stanley maintains the purchase rating of BICARA (BCAX) after the FICERAFUSP ALFA Trial Update
On May 23rd, Judah Frommer of Morgan Stanley appeared on Bicara Therapeutics Inc. (NASDAQ:bcax)While keeping the price target at $36.
This occurred after the company released preliminary data from the Phase 1/1B exam for Ficerafusp ALFA.
Close-up of a lab scientist performing tests with humanized immunoglobulin G1.
Bicara Therapeutics Inc. (NASDAQ: BCAX) is a clinical stage biopharmaceutical company that develops innovative bifunctional antibody therapies for solid tumors. Ficerafusp Alfa has been tested to enhance tumor penetration and to overcome the immunosuppressive tumor microenvironment, where the therapeutic efficacy of solid tumors is historically limited.
Recent data from the Phase 1/1B study show promising results in the treatment of HPV-negative patients with head and neck squamous cell carcinoma. Analysts highlighted that they reported median overall survival of >20 months, including a full response rate of 18-21%. Frommer believes this is a significant improvement compared to standard care, suggesting that Ficerafusp ALFA approval could be a breakthrough in the field of treatment that is difficult to obtain.
While we acknowledge the potential as an investment in BCAX, our conviction lies in the belief that some AI stocks offer higher returns and hold the greater promise of limited downside risk. If you’re looking for AI stocks that are more promising than BCAX and have a potential of 100 times upside, then Cheapest AI stocks.
Read next: According to analysts, 11 most promising new technology stocks and 12 Best Growth Stocks to Buy and Hold in the Long Term.
Disclosure: None.